Cardiac autonomic testing and treating heart disease. “A clinical perspective”

Heart International

Volumn 9, Issue 2, 2014, Pages 45-52

  Depace, Nicholas L ^a   Mears, Joy P ^b   Yayac, Michael ^c   Colombo, Joseph ^d  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b EASTERN UNIVERSITY   (United States)

^c DREXEL UNIVERSITY   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac autonomic neuropathy; Cardiovascular risk factors; Heart disease; Mortality

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; VALSARTAN;

AUTONOMIC DYSFUNCTION; CARDIAC AUTONOMIC NEUROPATHY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE VARIABILITY; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC HEART DISEASE; MICROALBUMINURIA; PARASYMPATHETIC TONE; REVIEW; SILENT MYOCARDIAL ISCHEMIA; SUDDEN CARDIAC DEATH; SYMPATHETIC TONE; VAGUS TONE;

EID: 84939247445     PISSN: 18261868     EISSN: 20362579     Source Type: Journal    
DOI: 10.5301/heartint.5000216     Document Type: Review

References (82)

1. Cammann H, Michel J. How to avoid misinterpretation of heart rate variability power spectra? Comput Methods Programs Biomed. 2002;68(1):15-23
2. Badra LJ, Cooke WH, Hoag JB, et al. Respiratory modulation of human autonomic rhythms. Am J Physiol Heart Circ Physiol. 2001;280(6):H2674-H2688
3. Hayano J, Mukai S, Sakakibara M, Okada A, Takata K, Fujinami T. Effects of respiratory interval on vagal modulation of heart rate. Am J Physiol. 1994;267(1 Pt 2):H33-H40
4. Eckberg DL. Physiological basis for human autonomic rhythms. Ann Med. 2000;32(5):341-349
5. Brown TE, Beightol LA, Koh J, Eckberg DL. Important influence of respiration on human R-R interval power spectra is largely ignored. J Appl Physiol (1985). 1993;75(5):2310-2317
6. Novak V, Novak P, de Champlain J, Le Blanc AR, Martin R, Nadeau R. Influence of respiration on heart rate and blood pressure fluctuations. J Appl Physiol (1985). 1993;74(2):617-626
7. Parati G, Rizzoni D. Assessing the prognostic relevance of blood pressure variability: discrepant information from different indices. J Hypertens. 2005;23(3):483-486
8. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387-397
9. Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-828
10. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 1981;213(4504):220-222
11. Akselrod S, Gordon D, Madwed JB, Snidman NC, Shannon DC, Cohen RJ. Hemodynamic regulation: investigation by spectral analysis. Am J Physiol. 1985;249(4 Pt 2):H867-H875
12. Akselrod S, Eliash S, Oz O, Cohen S. Hemodynamic regulation in SHR: investigation by spectral analysis. Am J Physiol. 1987;253(1 Pt 2):H176-H183
13. Akselrod S. Spectral analysis of fluctuations in cardiovascular parameters: a quantitative tool for the investigation of autonomic control. Trends Pharmacol Sci. 1988;9(1):6-9
14. Aysin B, Aysin E. Effect of respiration in heart rate variability (HRV) analysis. Conf Proc IEEE Eng Med Biol Soc. 2006;1:1776-1779
15. Aysin B, Aysin E, Colombo J. Comparison of HRV analysis methods during orthostatic challenge: HRV with respiration or without? IEEE Engineering in Medicine and Biology Conference, Lyons, France, 2007
16. Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med. 1980;92(2 Pt 2):308-311
17. Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol. 1998;31(3):593-601
18. Vinik AI, Maser RE, Nakave AA. Diabetic cardiovascular autonomic nerve dysfunction. US Endocrine Disease. 2007;Dec:2-9
19. Curtis BM, O’Keefe JH Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002;77(1):45-54
20. Vinik AI, Murray GL. Autonomic neuropathy is treatable. US Endocrinol. 2008;2:82-84
21. Nanavati SH, Bulgarelli RJ, Vazquez-Tanus J, Ghosh-Dastidar S, Colombo J, Arora RR. Altered autonomic activity with atrial fibrillation as demonstrated by non-invasive autonomic monitoring. US Cardiology. 2010;7(1):47-50
22. Tobias H, Vinitsky A, Bulgarelli RJ, Ghosh-Dastidar S, Colombo J. Autonomic nervous system monitoring of patients with excess parasympathetic responses to sympathetic challenges—clinical observations. US Neurology. 2010;5(2):62-66
23. DePace NL, Dowinsky SK. The heart repair manual: The Philadelphia formula program for preventing and reversing atherosclerosis. New York, NY: W. W. Norton & Company; 1993
24. Ahrens EH Jr. The management of hyperlipidemia: whether, rather than how. Ann Intern Med. 1976;85(1):87-93
25. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis. 2007;49(3):373-382
26. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225-1228
27. Pyörälä K, Ballantyne CM, Gumbiner B, et al.; Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 2004;27(7):1735-1740
28. Crea F, Monaco C, Lanza GA, et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clin Cardiol. 2002;25(10):461-466
29. Robins S, Ballantyne CM, Olsson AG, et al. Low high-density lipoprotein cholesterol and response to simvastatin therapy in Scandinavian Simvastatin Survival Study (4S). Circulation. 2002;106(2):e8, author reply e8
30. Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J. 2001;141(6):957-963
31. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol. 2000;86(3): 257-262
32. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159(22):2661-2667
33. Pedersen TR. Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol. 1998;82(10) (10B):53T-56T.
34. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-2087
35. Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol. 2008;52(1):24-32
36. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Effects of obesity on lipidlowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol. 2006;97(11): 1553-1557
37. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011;57(16):1666-1675
38. Filippone EJ, Foy A, Newman E. Goal-directed antihypertensive therapy: lower may not always be better. Cleve Clin J Med. 2011;78(2):123-133
39. Bangalore S, Steg G, Deedwania P, et al.; REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-1349
40. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-1579
41. Tsuji H, Venditti FJ Jr, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994;90(2):878-883
42. DePace NL, Mears JP, Yayac M, Colombo J. Cardiac autonomic testing and diagnosing heart disease. “A clinical perspective.” Heart Int. 2014;9(2):37-44
43. Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29(2):334-339
44. Pop-Busui R, Evans GW, Gerstein HC, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33(7):1578-1584
45. Istenes I, Keresztes K, Hermányi Z, et al. Relationship between autonomic neuropathy and hypertension—are we underestimating the problem? Diabet Med. 2008;25(7):863-866
46. Astrup AS, Nielsen FS, Rossing P, et al. Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens. 2007;25(12):2479-2485
47. Barthel P, Bauer A, Müller A, et al. Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction. Diabetes Care. 2011;34(8):1833-1837
48. Liao D, Cai J, Rosamond WD, et al. Cardiac autonomic function and incident coronary heart disease: a population-based casecohort study. The ARIC Study. Atherosclerosis Risk in Communities Study. Am J Epidemiol. 1997;145(8):696-706
49. Huikuri HV, Jokinen V, Syvänne M, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1999;19(8):1979-1985
50. Wackers FJT, Young LH, Inzucchi SE, et al.; Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004;27(8):1954-1961
51. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al.; American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118(17):1768-1775
52. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005;11(9):693-699
53. Copie X, Lamaison D, Salvador M, et al.; VALID Investigators. Heart rate variability before ventricular arrhythmias in patients with coronary artery disease and an implantable cardioverter defibrillator. Ann Noninvasive Electrocardiol. 2003;8(3): 179-184
54. Alter P, Grimm W, Vollrath A, Czerny F, Maisch B. Heart rate variability in patients with cardiac hypertrophy—relation to left ventricular mass and etiology. Am Heart J. 2006;151(4):829-836
55. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(Suppl 1):S11-S66
56. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33(Suppl 1):S11-S61
57. Gentlesk PJ, Wiley T, Taylor AJ. A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. Am Heart J. 2005;150(3):478-483
58. Arora RR, Bulgarelli RJ, Ghosh-Dastidar S, Colombo J. Autonomic mechanisms and therapeutic implications of postural diabetic cardiovascular abnormalities. J Diabetes Sci Tech. 2008;2(4): 645-657
59. Vinik AI, Arora RR, Colombo J. Age matched attenuation of both autonomic branches in chronic disease: II. Diabetes mellitus. Cleveland Clinic Heart-Brain Summit, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, 23-24 September 2010
60. Pereira E, Baker S, Bulgarelli RJ, Murray G, Arora RR, Colombo J. Gender differences in longevity and sympathovagal balance. Presented at the Cleveland Clinic Heart-Brain Summit, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, 23-24 September 2010
61. Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care. 2010;33(7):1688-1690
62. Vinik AI, Maser RE, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope? Diabet Med. 2011;28(6):643-651
63. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105(22):2595-2599
64. Su S, Lampert R, Zhao J, et al. Pleiotropy of C-reactive protein gene polymorphisms with C-reactive protein levels and heart rate variability in healthy male twins. Am J Cardiol. 2009;104(12):1748-1754
65. Gerstein HC, Mann JFE, Yi Q, et al.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286(4):421-426
66. Hermans MMH, Henry R, Dekker JM, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol. 2007;18(6):1942-1952
67. Hermans MMH, Henry RMA, Dekker JM, Nijpels G, Heine RJ, Stehouwer CDA. Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study. J Hypertens. 2008;26(4):791-797
68. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after longterm treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis. 2001;157(2):463-469
69. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670): 1175-1182
70. Fauci AS, Braunwald E, Kasper DL, et al. Harrison’s principles of internal medicine. 17th ed. New York, NY: McGraw-Hill Professional; 2008
71. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001; 104(18):2158-2163
72. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation. 1998;97(21): 2110-2116
73. Centers for Disease Control and Prevention (CDC). Decline in deaths from heart disease and stroke—United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999;48(30):649-656
74. Myerburg RJ. Scientific gaps in the prediction and prevention of sudden cardiac death. J Cardiovasc Electrophysiol. 2002; 13(7):709-723
75. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation. 2004;110(5):522-527
76. Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation. 1999;99(15):1978-1983
77. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330(15):1041-1046
78. Jouven X, Lemaître RN, Rea TD, Sotoodehnia N, Empana JP, Siscovick DS. Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J. 2005;26(20):2142-2147
79. Kannel WB, Cupples LA, D’Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J. 1987;113(3):799-804
80. Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. 2006;47(6): 1161-1166
81. Buxton AE, Ellison KE, Kirk MM, et al. Primary prevention of sudden cardiac death: trials in patients with coronary artery disease. J Interv Card Electrophysiol. 2003;9(2):203-206
82. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23): 1667-1675.